CoChat

The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy

Parsons, Bruce, Li, Chunming · 2016 · Current Medical Research and Opinion

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Objective To compare the therapeutic response to pregabalin in patients with moderate or severe painful diabetic peripheral neuropathy (pDPN). Research design and methods Data were pooled from 11 placebo-controlled trials to evaluate the efficacy of pregabalin flexible or fixed dose (150, 300 or 600 mg/day) in pDPN patients with mean baseline pain scores of ≥4 to <7 (moderate) or ≥7 to ≤10 (severe). Last observation carried forward imputation was used. Study number/ClinicalTrials.gov identifier 1008-014/-, 1008-029/-, 1008-040/-, 1008-131/-, 1008-149/-, 1008-000-155/-, A0081030/NCT00156078, A0081060/NCT00159679, A0081071/NCT00143156, A0081081/NCT00301223, A0081163/NCT00553475. Main outcome measures Pregabalin-mediated change in pain, pain-related sleep interference (PRSI) and patient global impression of change (PGIC) were compared versus placebo and between moderate and severe pain cohorts. Adverse events (AEs) were reported. Results At baseline, 1816 patients had moderate pain (pregabalin, n = 1189) and 1119 patients had severe pain (pregabalin, n = 720). Pregabalin significantly reduced pain scores at endpoint compared with placebo when patients of all pain levels were combined (all doses; p < 0.05). In the moderate and severe pain cohorts, pregabalin treatment (300, 600 mg/day or flexible) significantly reduced mean pain scores at endpoint compared with placebo (p < 0.01). Pain reduction was greatest in patients with severe baseline pain compared with moderate baseline pain (pregabalin 300, 600 mg/day or flexible; p < 0.0001). Pregabalin improved PRSI and PGIC in the moderate and severe cohorts compared with placebo. The greatest improvement in PRSI also occurred in the severe cohort. Treatment-emergent AEs, most commonly dizziness, somnolence and peripheral edema, occurred more frequently in patients treated with pregabalin compared with placebo. Conclusions Pregabalin was effective in pDPN patients with both moderate and severe baseline pain. Patients with severe pain exhibited greater improvements in pain and PRSI than patients with moderate pain. Pain severity may, in part, predict therapeutic response to pregabalin.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007995.2016.1151776

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Pal D, 2007, Indian J Med Res, 125, 721

Cited by

See all 20

Metadata

Authors
Parsons, B., & Li, C.
Affiliations
Pfizer (United States) (US)
Corresponding author
Parsons, Bruce
Venue
Current Medical Research and Opinion
Published
2016-03-08
Volume
32
Issue
5
Pages
929-937
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2280631568
Cited by
20
References
39
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2 · 2019: 3 · 2018: 7 · 2017: 2 · 2016: 1
FWCI
0.51
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
pregabalin, diabetic neuropathic pain, neuropathic pain, pain intensity, Patient Global Impression of Change, adverse events, dose comparison, flexible dosing, meta-analysis of trials, treatment efficacy, sleep disorders, quality of life, anxiety, cognitive impairment, dizziness, sleepiness
MeSH terms
Pregabalin, Adult, Aged, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Neuralgia, Pain Measurement, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy. https://app.cochat.ai/papers/10.1185/03007995.2016.1151776
The paper
Parsons, B., & Li, C. (2016). The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy. Current Medical Research and Opinion. https://doi.org/10.1185/03007995.2016.1151776

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.